focus -WSS

focus

author：hotspot 2025-10-01 14:19:00 - browse：4297

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Eli Lilly buys Point Biopharma in radiopharmaceuticals play

WSS

HHS secretary Becerra pressed on Change HealthCare cyberattack

Steward Health Care Massachusetts hospitals face fiscal disaster

FDA panel signals lack of confidence in Amgen cancer drug data

A virus, fished out of a lake, may have saved a man’s life

Was Amgen transparent enough on FDA's concern on cancer drug?

FDA authorizes Novavax’s updated Covid

leisure time

focus

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

Amid AI frenzy, a top HHS official's quest to create safeguards

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Duchenne breakthrough therapy leaves behind pioneering families

FDA advisers back CAR

Affirmative action in medical school literally saved lives

President Biden's budget: Here's what you might have missed

The cancer drug shortage isn’t new — and neither are the solutions

Bill would stop addiction treatment from triggering child abuse inquiry

Wikipedia

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Why scientists need input from humanists on sensitive research

RaDonda Vaught links Vanderbilt hospital issues to patient death

Bill would stop addiction treatment from triggering child abuse inquiry

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Bill would stop addiction treatment from triggering child abuse inquiry

leisure time

Wikipedia

focus

explore